Affiliation:
1. Biotrial S.A.; Rennes France
2. Takeda Development Centre Europe Ltd; London UK
Funder
Takeda Pharmaceutical Company
Subject
General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience
Reference17 articles.
1. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamin e monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases;Hori;J. Pharmacol. Exp. Ther.,2010
2. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases;Andersson;Pharmacol, Ther,2005
3. Takeda New drug application approval of TAKECAB ® for the treatment of acid-related diseases in Japan (press release) http://www.takeda.com
4. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male Japanese/non-Japanese subjects;Sakurai;Clin. Transl. Gastroenterol.,2015
5. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects;Jenkins;Aliment. Pharmacol. Ther.,2015
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献